Skip to main content

For questions about financial assistance,
call 1-844-DUPIXENT, option 1 or
click to learn more  

  • VIEW ALL CONDITIONS
  • Choose Your Language
    • 中文網站
    • Sitio web en español
  • View HCP Site
  • Prescribing & Patient Information
    • PATIENT INFORMATION
    • Patient Information - English
    • Patient Information - Spanish
    • Patient Information - Chinese

    • PRESCRIBING INFORMATION
    • Prescribing Information - English
    • Prescribing Information - Spanish
    • Prescribing Information - Chinese

    • PRE-FILLED SYRINGE INSTRUCTIONS FOR USE
    • 200 mg Syringe - English
    • 200 mg Syringe - Spanish
    • 200 mg Syringe - Chinese
    • 300 mg Syringe - English
    • 300 mg Syringe - Spanish
    • 300 mg Syringe - Chinese

    • PRE-FILLED PEN INSTRUCTIONS FOR USE
    • 200 mg Pen - English
    • 200 mg Pen - Spanish
    • 200 mg Pen - Chinese
    • 300 mg Pen - English
    • 300 mg Pen - Spanish
    • 300 mg Pen - Chinese
  • Copay Offer
  • FOR U.S.
    RESIDENTS ONLY
Dupixent® (dupilumab) Injection (200 mg or 300 mg) logo
Cost & Savings Get Email Updates
  • Home
  • About
    Eczema
    • What Is Eczema?
    • Eczema Across
      Skin Tones
  • About
    Dupixent
    • How DUPIXENT
      Works
    • Dosing for Eczema
    • Real Patient
      Stories
    • FAQs
  • Dupixent
    Results
    • Adults (18+ Yrs)
    • Teens (12-17 Yrs)
    • Children (6-11 Yrs)
    • Young Children
      (6 Mos-5 Yrs)
  • Asking About
    Dupixent
    • Find an Eczema
      Specialist
    • Prepare for Your
      Doctor's Visit
  • Starting
    Dupixent
    • Copay Card
    • Cost & Savings
    • Injection Support
      Center
  • Resources
    & Support
    • Patient Support
      Program
    • Caregiver
      Resources
    • Connect With a Mentor
    • Webinars & Events
    • Injection Reminders and Tips
  • 中文網站
  • Sitio web en español
  • View HCP Site
  • Copay Offer

Important Safety Information and Indication

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

  • have eye problems.
  • have a parasitic (helminth) infection.
  • are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.
  • are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
    • A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/.
  • are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines or if you have atopic dermatitis and asthma and use an asthma medicine. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

  • Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue, or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area.
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an eye exam if needed.
  • Psoriasis. This can happen in people with atopic dermatitis who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.
  • Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.

The most common side effects in patients with eczema include injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full accompanying full Prescribing Information including Patient Information.

Indication

DUPIXENT is a prescription medicine used to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age.

Sanofi® Logo

Regeneron® Logo

Site Map
Legal Disclaimer Information

Questions or comments?
Contact Sanofi US or Regeneron Pharmaceuticals, Inc or call 1-844-387-4936
to contact DUPIXENT MyWay®.

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology.
 

Sanofi US is hosting this website on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron are industry partners, who are committed to handling personal data in ways that respect your privacy. Both companies may independently process your personal data to manage patient support programs and product marketing campaigns. Please refer to Regeneron’s Privacy Notice and Consumer Health Data Privacy Policy and Sanofi’s Privacy Policy and Consumer Health Data Privacy Policy and Cookies Policy for more information regarding processing of your personal data.

Are you sure you want to leave?

Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to their website visitors and users; however, they take no responsibility for the information on any website but their own.

This DUPIXENT® (dupilumab) website is for U.S. healthcare professionals only. Click "continue" only if you are a U.S. healthcare professional.

US-DAS-1231(1)

Enter your email address and we will send you your requested resource.

Success!

Your email is on its way. Be sure to check your inbox.

Enter your email address and we will send you your personalized guide.

Success!

Your email is on its way. Be sure to check your inbox.

Rate your conversation

Thanks for the feedback!